Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s strong progress across its proprietary diabetes and obesity pipeline and partnerships. The discussion followed the release of Arecor Therapeutics’ full-year 2024 results, where Howell detailed advances in AT278 — a highly concentrated, ultra-rapid acting insulin shown to be effective in patients with Type 2 diabetes and high BMI.
AT278, according to Howell, delivers faster insulin onset and superior glucose control compared to current market alternatives. “We got more insulin on board faster,” she said, highlighting the product’s pharmacokinetic and pharmacodynamic advantages. She added that the insulin is particularly suited for use in insulin pump therapies, especially for patients requiring high daily doses — a segment traditionally underserved by existing pump solutions.
Beyond injectables, Arecor has entered the oral peptide delivery space with a new platform targeting enhanced bioavailability, initially focusing on oral GLP-1 for obesity. Howell noted, “We have overcome the first significant challenges of stabilising the peptide,” using the company’s Arestat technology, with semaglutide development underway to improve upon existing oral GLP-1 drugs like Rybelsus.
The company continues to expand its partner network and revenue-generating collaborations. It expects key data from oral peptide studies and a potential strategic partnership announcement for AT278 during 2025.
For more insightful updates from biotech and pharma leaders, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications to stay updated!
#ArecorTherapeutics #AT278 #InsulinPump #GLP1 #DiabetesTreatment #ObesityDrugs #BiotechNews #PharmaInnovation #Semaglutide #OralDelivery #DrugDevelopment #ProactiveInvestors
